← Eichor
Condition: Ras Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ras Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-S
Phase 2 · 13 location(s) · Oncolytics Biotech · NCT07446322A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 · 3 location(s) · RasCal Therapeutics, Inc. · NCT04678648A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Phase 2 · 19 location(s) · Verastem, Inc. · NCT07644559XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05970302A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Phase 1 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07189949Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS
Phase 2 · 1 location(s) · Fudan University · NCT06218810Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Muta
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03190941Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT03454035Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/Phase 2 · 6 location(s) · Revolution Medicines, Inc. · NCT07397338cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224815ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Phase 2 · 1 location(s) · Beijing Hospital · NCT06321081Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Phase 2 · 1 location(s) · N.N. Petrov National Medical Research Center of Oncology · NCT06229340Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
Phase N/A · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT06449989Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06763029Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Phase 1/Phase 2 · 18 location(s) · Tango Therapeutics, Inc. · NCT06922591Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/Phase 2 · 93 location(s) · Revolution Medicines, Inc. · NCT06162221Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer
NA · 37 location(s) · Technische Universität Dresden · NCT04678583Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Phase 1 · 3 location(s) · Shanghai YingLi Pharmaceutical Co. Ltd. · NCT06096974Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Pa
Phase 2 · 1 location(s) · Sergey Orlov, MD · NCT06949982Hematological Anomalies in Children With Rasopathy
Phase N/A · 14 location(s) · Assistance Publique - Hôpitaux de Paris · NCT04286360Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/Phase 2 · 21 location(s) · Revolution Medicines, Inc. · NCT05379985A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Pa
Phase 1 · 21 location(s) · Hoffmann-La Roche · NCT06884618Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-me
Phase 3 · 1 location(s) · Caigang Liu · NCT06566755MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05735717A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Phase 1 · 23 location(s) · Nested Therapeutics, Inc · NCT06326411Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224841A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Phase 1 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07142980Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Phase 1 · 9 location(s) · Revolution Medicines, Inc. · NCT07349537
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.